logo

HITAP เข้าสู่ระบบ

ลืมรหัสผ่าน?

Economic evaluation of HMG-CoA reductase inhibitors (statin) for primary prevention of cardiovascular diseases among Thai population (in Thai language)

Home > Research Projects > Strategy 3 : HTA Research > Economic evaluation of HMG-CoA reductase inhibitors (statin) for primary prevention of cardiovascular diseases among Thai population (in Thai language)

Project Code

01-308-2550

Research team

Researchers

Yupin Tamteerano, B.Pharm

Co - Researcher

Panrasri Khonputsa

Yot Teerawattananon, PhD.

Usa Chaikledkaew, PhD.

Stephen Lim

Project Details

Strategies
Category
Support
Project duration

Start: - 2007
End: -

Contact
[email protected]

Project Status

Completed - 100%

Viewer: 2776

Publish date26 November 2011 06:20

Project Summary

The aims of this study were 1) to estimate the incremental cost-effectiveness ratio (ICER) of offering statins for primary prevention of CVD for each CVD risk group, and 2) to estimate the budget impact if the statins were prescribed to those people living with different CVD risks. This was a model-based economic evaluation. A Markov model was constructed to estimate the costs and benefits in terms of quality adjusted life year (QALY) gained by providing statins in comparison to a “null” or “do nothing” scenario. The study revealed that if a ceiling threshold is equal to 3 times that of Gross Domestic Product per capita or 300,000 Baht per QALY, a generic simvastatin is a cost-effective intervention for all people except those with less than 2.5% CV D risk. However, if the ceiling threshold is equal to 100,000 Baht per QAL Y, a generic simvastatin is still considered as a cost-effective intervention if it is offered to Thai people with > 30% CVD risk.

Documents

Activity

โครงการประเมินเทคโนโลยีและนโยบายด้านสุขภาพ ชั้น 6 อาคาร 6 กรมอนามัย กระทรวงสาธารณสุข ถ.ติวานนท์ อ.เมือง จ.นนทบุรี 11000

โทร : +662-590-4549 , +662-590-4374-5
โทรสาร : +662-590-4369
E-mail : [email protected]

© Copyright - HITAP 2014
Top